Pharmaceutical

Generalized Pustular Psoriasis (GPP) drugs in development, 2024

GlobalData tracks 6 drugs in development for Generalized Pustular Psoriasis (GPP) by five companies/universities/institutes. The top development phase for Generalized Pustular Psoriasis (GPP) is preclinical, with two drugs in that stage.

Aug 31, 2024 - 04:00
GlobalData tracks 6 drugs in development for Generalized Pustular Psoriasis (GPP) by five companies/universities/institutes. The top development phase for Generalized Pustular Psoriasis (GPP) is preclinical, with two drugs in that stage.
Read the original article

Tags:

Previous Article

Atypical Teratoid Rhabdoid Tumor drugs in development, 2024

Next Article

Frontotemporal Dementia (FTD) drugs in development, 2024

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

JURA Bio and Syena partner to develop TCR-based therapies

JURA Bio and Syena partner to develop TCR-based therapies

Sep 23, 2023

Biotech survey highlights where industry can focus for a thriving future  

Biotech survey highlights where industry can focus for ...

Jul 12, 2024

LakeShore commences BLA submission to DRAP for rabies vaccine

LakeShore commences BLA submission to DRAP for rabies v...

Nov 9, 2024